SEC Form 3 · accession 0001209191-15-006594
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter E. Daddona
Officer — Chief Scientific Officer · Director
Period of report
Jan 26, 2015
Accepted (ET)
Jan 26, 2015 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 318,787 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $1.40 | holding | — | — | — | — | Jun 15, 2022 | Common Stock | 70,753 | — | D |
Explanation of responses
- F1The option became exercisable as to 17,688 shares on June 15, 2013 and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years; provided that if the holder is terminated without cause or resigns for good reason (as these terms are defined in the holder's employment agreement), then the option will become exercisable for an additional 18.75% of the total underlying shares; provided further that if the option holder is terminated without cause or resigns for good reason within one year after a change in control (as defined in the holder's employment agreement), then the option will become exercisable for 100% of the underlying shares.